Skip to content

Prospective study of efficacy and safety of preoperative transcatheter arterial chemolipiodolization with miriplatin for hepatocellular carcinoma.(Phase I study)

Prospective study of efficacy and safety of preoperative transcatheter arterial chemolipiodolization with miriplatin for hepatocellular carcinoma.(Phase I study) - Phase I trial of preoperative Chemolipiodolization with miriplatin for hepatocellular carcinoma.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000010123
Enrollment
6
Registered
2013-02-26
Start date
2013-02-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Transcatheter arterial chemolipiodolization with miriplatin

Sponsors

Second department of surgery, Dokkyo Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age over 20 years old. 2) Written informed consent 3) The tumor number <= 3 nodules in the liver. The maximum tumor diameter without limit. 4) Adequate organ function for 2 weeks before transcatheter arterial chemolipiodolization with miriplatin.

Exclusion criteria

Exclusion criteria: 1) Patients who have medical history of hypersensitivity of platinum-containing drug, iodine-containing drug and gelatine. 2) Patients with serious complications(Severe thyroid disease, Severe heart disease and the like) 3) Patients with active double cancer. 4) Patients with bile duct invasion. 5) Pregnant and lactating females; males and females of childbearing age unless using effective contraception. 6) Patients without remarkable findings of A-V shunt and/or A-P shunt. 7) Tumor thrombosis in main portal vein or vena cava. 8) Patients who are concluded to be inappropriate to participate in this study by their physicians.

Design outcomes

Primary

MeasureTime frame
Safety

Secondary

MeasureTime frame
Operative duration, Intraoperative blood loss, Hospital stay, Complications

Countries

Japan

Contacts

Public ContactMasato Kato

Dokkyo Medical University Second department of surgery

katomasa@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026